| Brett Zerbinopoulos, OD | |
|
623 Atwells Ave, Providence, RI 02909-7403 | |
| (401) 273-7100 | |
| Not Available |
| Full Name | Brett Zerbinopoulos |
|---|---|
| Gender | Male |
| Speciality | Optometry |
| Experience | 4 Years |
| Location | 623 Atwells Ave, Providence, Rhode Island |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144846478 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 152W00000X | Optometrist | ODTG00698 (Rhode Island) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Toll Gate Vision, Ltd. | 7911048533 | 3 |
| Ezra L Galler Md Ltd | 8921067349 | 4 |
News Archive
Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.
The Wall Street Journal reports that, in a party-line vote Saturday night, "Democratic leaders finally moved their sweeping health bill to the Senate floor, where wheeling and dealing over major unresolved and divisive issues likely will shape the legislation before its next big test." Some centrists are busy saying they won't support a bill with a government-run public option in it. They are also divided over abortion.
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.
House Republicans' irresponsible brinkmanship may finally lead to the government shutdown that some of its members have been coveting since they took control of that chamber in 2011. This time, though, the fight hasn't been a battle over spending on federal agencies. It's been a symbolic one over the 2010 Patient Protection and Affordable Care Act, a.k.a. Obamacare. And it's been a sham. The inconvenient truth for the GOP is that "defunding Obamacare," as the House tried to do, wouldn't stop most of the major provisions of the health care law, some of which have already gone into effect
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
› Verified 6 days ago
| Provider Name | Ezra L Galler Md Ltd |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1184630717 PECOS PAC ID: 8921067349 Enrollment ID: O20041011000005 |
News Archive
Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.
The Wall Street Journal reports that, in a party-line vote Saturday night, "Democratic leaders finally moved their sweeping health bill to the Senate floor, where wheeling and dealing over major unresolved and divisive issues likely will shape the legislation before its next big test." Some centrists are busy saying they won't support a bill with a government-run public option in it. They are also divided over abortion.
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.
House Republicans' irresponsible brinkmanship may finally lead to the government shutdown that some of its members have been coveting since they took control of that chamber in 2011. This time, though, the fight hasn't been a battle over spending on federal agencies. It's been a symbolic one over the 2010 Patient Protection and Affordable Care Act, a.k.a. Obamacare. And it's been a sham. The inconvenient truth for the GOP is that "defunding Obamacare," as the House tried to do, wouldn't stop most of the major provisions of the health care law, some of which have already gone into effect
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
› Verified 6 days ago
| Provider Name | Family Eye Health Associates, Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1598911224 PECOS PAC ID: 1850454448 Enrollment ID: O20090108000014 |
News Archive
Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.
The Wall Street Journal reports that, in a party-line vote Saturday night, "Democratic leaders finally moved their sweeping health bill to the Senate floor, where wheeling and dealing over major unresolved and divisive issues likely will shape the legislation before its next big test." Some centrists are busy saying they won't support a bill with a government-run public option in it. They are also divided over abortion.
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.
House Republicans' irresponsible brinkmanship may finally lead to the government shutdown that some of its members have been coveting since they took control of that chamber in 2011. This time, though, the fight hasn't been a battle over spending on federal agencies. It's been a symbolic one over the 2010 Patient Protection and Affordable Care Act, a.k.a. Obamacare. And it's been a sham. The inconvenient truth for the GOP is that "defunding Obamacare," as the House tried to do, wouldn't stop most of the major provisions of the health care law, some of which have already gone into effect
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
› Verified 6 days ago
| Provider Name | Toll Gate Vision, Ltd. |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1265604862 PECOS PAC ID: 7911048533 Enrollment ID: O20100105000323 |
News Archive
Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.
The Wall Street Journal reports that, in a party-line vote Saturday night, "Democratic leaders finally moved their sweeping health bill to the Senate floor, where wheeling and dealing over major unresolved and divisive issues likely will shape the legislation before its next big test." Some centrists are busy saying they won't support a bill with a government-run public option in it. They are also divided over abortion.
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.
House Republicans' irresponsible brinkmanship may finally lead to the government shutdown that some of its members have been coveting since they took control of that chamber in 2011. This time, though, the fight hasn't been a battle over spending on federal agencies. It's been a symbolic one over the 2010 Patient Protection and Affordable Care Act, a.k.a. Obamacare. And it's been a sham. The inconvenient truth for the GOP is that "defunding Obamacare," as the House tried to do, wouldn't stop most of the major provisions of the health care law, some of which have already gone into effect
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Brett Zerbinopoulos, OD 22 Carrie Ln, North Kingstown, RI 02852-4138 Ph: (401) 295-7050 | Brett Zerbinopoulos, OD 623 Atwells Ave, Providence, RI 02909-7403 Ph: (401) 273-7100 |
News Archive
Areas of the brain that respond to reward and pleasure are linked to the ability of a drug known as butorphanol to relieve itch, according to new research led by Gil Yosipovitch, MD, Professor and Chairman of the Department of Dermatology at Temple University School of Medicine, and Director of the Temple Itch Center.
The Wall Street Journal reports that, in a party-line vote Saturday night, "Democratic leaders finally moved their sweeping health bill to the Senate floor, where wheeling and dealing over major unresolved and divisive issues likely will shape the legislation before its next big test." Some centrists are busy saying they won't support a bill with a government-run public option in it. They are also divided over abortion.
Indevus Pharmaceuticals, Inc. has announced that it has entered into a co-promotion and licensing agreement with PLIVA d.d. through its specialty branded subsidiary, Odyssey Pharmaceuticals Inc., for the U.S. commercialization of SANCTURA™ (trospium chloride), under review by the U.S. Food and Drug Administration (FDA) as a treatment for overactive bladder.
House Republicans' irresponsible brinkmanship may finally lead to the government shutdown that some of its members have been coveting since they took control of that chamber in 2011. This time, though, the fight hasn't been a battle over spending on federal agencies. It's been a symbolic one over the 2010 Patient Protection and Affordable Care Act, a.k.a. Obamacare. And it's been a sham. The inconvenient truth for the GOP is that "defunding Obamacare," as the House tried to do, wouldn't stop most of the major provisions of the health care law, some of which have already gone into effect
Noting that India's Supreme Court on Monday ruled that drug maker Novartis "should not be given a patent for a cancer drug because it was too similar to Novartis's earlier version," a New York Times editorial writes, "The decision, which is the culmination of a high-profile, seven-year legal battle, should help protect the availability of cheap generic drugs for poor patients."
› Verified 6 days ago
Dr. Robert Mitchell Thacker, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 1466 Broad St, Providence, RI 02905 Phone: 401-941-6221 Fax: 401-941-6227 | |
Rhode Island Eye Institute Optometrist Medicare: Medicare Enrolled Practice Location: 150 E Manning St, Providence, RI 02906 Phone: 401-272-2020 | |
Eye Care Services Optometrist Medicare: Not Enrolled in Medicare Practice Location: 740 N Main St, Providence, RI 02904 Phone: 401-272-8282 Fax: 401-272-8284 | |
Eyediology Vision, Llc Optometrist Medicare: Medicare Enrolled Practice Location: 245 Waterman St Ste 309, Providence, RI 02906 Phone: 732-668-9571 | |
East Side Vision Care Inc Optometrist Medicare: Not Enrolled in Medicare Practice Location: 213 Thayer St, Providence, RI 02906 Phone: 401-421-4500 Fax: 401-421-3876 | |
Stephanie Sturgis, OD Optometrist Medicare: Accepting Medicare Assignments Practice Location: 891 Westminster St, Providence, RI 02903 Phone: 401-331-7850 Fax: 401-274-4739 | |
Koch Eye Associates,llp Optometrist Medicare: Not Enrolled in Medicare Practice Location: 55 Dorrance St, Providence, RI 02903 Phone: 401-861-0220 Fax: 401-861-0079 |